Targeting an RNA Editor to Impede H3K27M+ Pediatric Gliomas

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Diffuse midline glioma (DMG) is a pediatric brain tumor with poor prognosis.
• Current immune checkpoint blockade (ICB) therapies show limited efficacy in DMG due to immune evasion mechanisms.

Purpose of the Study:

• To investigate the role of adenosine deaminase acting on RNA (ADAR) in immune evasion in H3K27M-mutant DMG.
• To identify therapeutic strategies to overcome immune evasion in DMG.

Main Methods:

• Analysis of ADAR expression in H3K27M-mutant DMG.
• Assessment of ADAR depletion effects on DMG cell proliferation and immune signaling.
• Evaluation of all-trans retinoic acid (ATRA) as an ADAR-targeting agent in preclinical DMG models.

Main Results:

• ADAR is overexpressed in H3K27M DMG, suppressing immune responses.
• ADAR loss or ATRA treatment increases retroelement expression, interferon signaling, and tumor immunogenicity.
• ATRA enhances T cell infiltration and synergizes with ICB and irradiation to improve survival in DMG models.

Conclusions:

• ADAR is a key mediator of immune evasion in H3K27M DMG.
• ATRA represents a promising therapeutic strategy to enhance anti-tumor immunity and treatment outcomes in pediatric DMG.